New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:19 EDTISIS, BIIBIsis to receive $9.3M in milestone payments for ongoing Phase 2 ISIS-SMN study
Isis Pharmaceuticals (ISIS) announced that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMNRx in children with spinal muscular atrophy. Isis also announced that the first child was dosed in an open–label extension study, which is being offered to those children with SMA who have completed dosing in Isis' previous studies. Isis will receive two milestone payments totaling $7.3M for advancements in these studies. Isis also announced that dosing in the Phase 2 study in infants with SMA is being extended. Under the extension, infants who have completed the three initially scheduled study doses will be eligible to receive an additional dose of 12 mg. Isis announced that the first infant in the study has received a fourth dose of ISIS-SMNRx approximately six months after the three initial doses were completed. For this achievement, Isis will receive a $2M milestone payment from Biogen Idec (BIIB).
News For ISIS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:24 EDTISISGoldman to hold a conference
Subscribe for More Information
06:40 EDTISISIsis Pharmaceuticals price target raised to $62 from $53 at Piper Jaffray
Subscribe for More Information
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 18, 2014
15:48 EDTISISGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
November 14, 2014
15:41 EDTISISIsis Pharmaceuticals management to meet with Piper Jaffray
Meeting to be held in Kansas City, MO on November 18 hosted by Piper Jaffray.
November 13, 2014
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
05:34 EDTISISAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
November 12, 2014
08:13 EDTBIIBBoston Biotech to hold a conference
Subscribe for More Information
07:53 EDTISISLeerink to hold a tour
Subscribe for More Information
November 10, 2014
16:07 EDTISISIsis Pharmaceuticals files to sell $425M in convertible senior notes due 2021
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use